Dopamine receptor agonists(continued)
(pramipexole). Adjust dose.oTheoretical→Also see
TABLE 8p. 848
▶Droperidolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶Ergometrineis predicted to increase the risk of ergotism when
given withdopamine receptor agonists(cabergoline, pergolide).
Avoid.oTheoretical
▶Ergotamineis predicted to increase the risk of ergotism when
given withdopamine receptor agonists(bromocriptine,
cabergoline). Avoid.oTheoretical
▶Ergotamineis predicted to increase the risk of ergotism when
given withpergolide.oTheoretical
▶Flupentixolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Apomorphineis predicted to increase the risk of severe
hypotension when given withgranisetron.rTheoretical
▶H 2 receptor antagonists(cimetidine)slightly increase the
exposure topramipexole. Adjust dose.oStudy
▶Haloperidolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849→Also seeTABLE 10p. 849
▶HIV-protease inhibitorsincrease the exposure tobromocriptine.
rStudy
▶HIV-protease inhibitorsare predicted to increase the
concentration ofcabergoline.oAnecdotal
▶Hormone replacement therapydecreases the clearance of
ropinirole. Monitor and adjust dose.oStudy
▶Idelalisibincreases the exposure tobromocriptine.rStudy
▶Idelalisibis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Imatinibis predicted to increase the exposure to
bromocriptine.rTheoretical
▶Imatinibis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Loxapineis predicted to decrease the effects ofdopamine
receptor agonists.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 10p. 849
▶Macrolides(clarithromycin)increase the exposure to
bromocriptine.rStudy
▶Macrolides(clarithromycin, erythromycin)are predicted to
increase the concentration ofcabergoline. Avoid.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tobromocriptine.rTheoretical
▶Amantadineincreases the risk of CNS toxicity when given with
memantine. Use with caution or avoid.rTheoretical
▶Memantineis predicted to increase the effects ofdopamine
receptor agonists(apomorphine, bromocriptine, cabergoline,
pergolide, pramipexole, quinagolide, ropinirole, rotigotine).
oTheoretical
▶Metoclopramideis predicted to decrease the effects of
dopamine receptor agonists(apomorphine, bromocriptine,
cabergoline, pergolide, pramipexole, quinagolide, ropinirole,
rotigotine). Avoid.oStudy
▶Netupitantis predicted to increase the exposure to
bromocriptine.rTheoretical
▶Netupitantis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Nilotinibis predicted to increase the exposure to
bromocriptine.rTheoretical
▶Nilotinibis predicted to increase the concentration of
cabergoline.oAnecdotal
▶Olanzapineis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Apomorphineincreases the risk of severe hypotension when
given withondansetron. Avoid.rStudy→Also seeTABLE 9
p. 849
▶Paliperidoneis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶Apomorphineis predicted to increase the risk of severe
hypotension when given withpalonosetron.rTheoretical▶Phenothiazinesare predicted to decrease the effects of
dopamine receptor agonists. Avoid.oTheoretical→Also
seeTABLE 8p. 848→Also seeTABLE 9p. 849→Also seeTABLE 10
p. 849
▶Pimozideis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849→Also seeTABLE 10p. 849
▶Quetiapineis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Quinolones(ciprofloxacin)are predicted to increase the
exposure toropinirole. Adjust dose.oStudy
▶Risperidoneis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶SSRIs(fluvoxamine)are predicted to increase the exposure to
ropinirole. Adjust dose.oStudy
▶Sulpirideis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶Sympathomimetics, vasoconstrictor(isometheptene)potentially
increase the risk of side-effects when given with
bromocriptine. Avoid.rAnecdotal
▶Zuclopenthixolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
Dorzolamide
ROUTE-SPECIFIC INFORMATIONSince systemic absorption can
follow topical application, the possibility of interactions
should be borne in mind.
Dosulepin→see tricyclic antidepressants
Doxapram
▶Aminophyllineincreases the risk of agitation when given with
doxapram.oStudy
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the effects ofdoxapram.o
Theoretical
▶Theophyllineincreases the risk of agitation when given with
doxapram.oStudy
Doxazosin→see alpha blockers
Doxepin→see tricyclic antidepressants
Doxorubicin→see anthracyclines
Doxycycline→see tetracyclines
Dronedarone→see antiarrhythmics
Droperidol→seeTABLE 8p. 848 (hypotension),TABLE 9p. 849 (QT-
interval prolongation),TABLE 11p. 849 (CNS depressant effects)
▶Droperidolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶Droperidolis predicted to decrease the effects ofguanethidine.
Monitor and adjust dose.oTheoretical→Also seeTABLE 8
p. 848
▶Droperidoldecreases the effects oflevodopa.rStudy→
Also seeTABLE 8p. 848
Drospirenone→seeTABLE 16p. 851 (increased serum potassium)
▶Antifungals, azoles(ketoconazole)moderately increase the
exposure todrospirenone.rStudy
Dulaglutide→seeTABLE 14p. 850 (antidiabetic drugs)
Duloxetine→seeTABLE 18p. 851 (hyponatraemia),TABLE 13p. 850
(serotonin syndrome),TABLE 4p. 847 (antiplatelet effects)
▶Antiepileptics(phenytoin)are predicted to decrease the
exposure toduloxetine.oTheoretical
▶Duloxetineis predicted to increase the exposure tobeta
blockers, selective(metoprolol).oStudy
▶Duloxetineis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶HIV-protease inhibitors(ritonavir)are predicted to decrease the
exposure toduloxetine.oTheoretical
▶Leflunomideis predicted to decrease the exposure to
duloxetine.oTheoretical
▶Duloxetineis predicted to increase the exposure topitolisant.
Use with caution and adjust dose.oStudy
▶Quinolones(ciprofloxacin)are predicted to increase the
exposure toduloxetine. Avoid.oTheoretical912 Dopamine receptor agonists—Duloxetine BNFC 2018 – 2019
Interactions|Appendix 1A1